Adaptimmune Therapeutics Plc Current ratio
Qual é o Current ratio de Adaptimmune Therapeutics Plc?
O Current ratio de Adaptimmune Therapeutics Plc é 3.09
Qual é a definição de Current ratio?
O índice atual é um índice de liquidez que mede se uma empresa possui ou não recursos suficientes para cumprir suas obrigações de curto prazo.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio de empresas na Setor Health Care em NASDAQ em comparação com Adaptimmune Therapeutics Plc
O que Adaptimmune Therapeutics Plc faz?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Empresas com current ratio semelhantes a Adaptimmune Therapeutics Plc
- PT Aneka Tambang Tbk tem Current ratio de 3.09
- The a2 Milk tem Current ratio de 3.09
- Zevia PBC tem Current ratio de 3.09
- PF tem Current ratio de 3.09
- Pipeline Engineering tem Current ratio de 3.09
- Secoo Ltd tem Current ratio de 3.09
- Adaptimmune Therapeutics Plc tem Current ratio de 3.09
- Larsen & Toubro Infotech tem Current ratio de 3.09
- Beauce Gold Fields tem Current ratio de 3.09
- KEI Industries tem Current ratio de 3.09
- Sohu.com tem Current ratio de 3.09
- The Peria Karamalai Tea and Produce tem Current ratio de 3.09
- Graphite India tem Current ratio de 3.09